이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Moderna 대차 대조표 상태

재무 상태 기준 확인 6/6

Moderna 의 총 주주 지분은 $12.8B 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $16.7B 및 $3.9B 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$8.49b
주식	US$11.71b
총 부채	US$3.97b
총 자산	US$15.68b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27

Moderna: Counting On Pipeline Too Much

Feb 23

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Feb 16

Moderna: Fade 2025 Outlook

Jan 15

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 29

재무 상태 분석

단기부채: MRNA 의 단기 자산 ( $9.7B )이 단기 부채( $2.4B ).

장기 부채: MRNA 의 단기 자산( $9.7B )이 장기 부채( $1.6B ).

부채 대 자본 내역 및 분석

부채 수준: MRNA 부채가 없습니다.

부채 감소: MRNA 5년 전에 부채가 없었습니다.

부채 범위: MRNA 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: MRNA 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Moderna 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Moderna: Still Bullish View

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Price target decreased by 16% to US$105

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Consensus revenue estimates fall by 21%

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Moderna, Inc. Announces Board Changes

Co-Founder notifies of intention to sell stock

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna: Really Strong Competition

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Co-Founder notifies of intention to sell stock

Moment Of Truth Approaches For Moderna's RSV Vaccine

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

Moderna Q1: A Promising Pipeline Is Undervalued

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Moderna: Considering The Cancer Vaccine Angle

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna Continues To Build A Pipeline

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Co-Founder notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

President notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Moderna: Counting On Pipeline Too Much

Moderna, Inc., Annual General Meeting, May 06, 2024

Consensus EPS estimates fall by 12%

CEO & Director recently sold US$2.3m worth of stock

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Moderna: Fade 2025 Outlook

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

President notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기